We are live on ! Find out more
BOCH

Blue Owl Capital Holdings Portfolio holdings

AUM $372M
1-Year Est. Return 78.25%
This Fund
S&P 500
This Quarter Est. Return
+4.2%
1 Year Est. Return
+78.25%
3 Year Est. Return
+112.77%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$372M
AUM Growth
+$48.1M
Cap. Flow
+$80.2M
Cap. Flow %
21.56%
Top 10 Hldgs %
69.34%
Holding
99
New
19
Increased
13
Reduced
16
Closed
23

Top Buys

Rank Stock Value
1
AKTS
Aktis Oncology
AKTS
+$61.4M
2
MPLT
MapLight Therapeutics
MPLT
+$12.1M
3
ENGN icon
enGene Therapeutics
ENGN
+$9.4M
4
CRVS icon
Corvus Pharmaceuticals
CRVS
+$8.7M
5
EYPT icon
EyePoint Inc
EYPT
+$7.78M

Top Sells

Rank Stock Value
1
RPTX
Repare Therapeutics
RPTX
+$8.95M
2
PCOR icon
Procore
PCOR
+$6.86M
3
ROIV icon
Roivant Sciences
ROIV
+$5.71M
4
CGEM icon
Cullinan Oncology
CGEM
+$5.67M
5
CNTX icon
Context Therapeutics
CNTX
+$5.47M

Sector Composition

Rank Sector Weight
1 Healthcare 76.1%
2 Financials 13.79%
3 Consumer Discretionary 4.78%
4 Technology 2.41%
5 Real Estate 0.73%

No holdings matched the selected filter criteria.

1 2 3 4

Similar funds

PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
PAA
Peregrine Asset Advisers Portland, Oregon $371M AUM 41.36% 1-Year Est. Return
JC
Joho Capital New York $373M AUM 18.89% 1-Year Est. Return

Blue Owl Capital Holdings's Q1 2026 Portfolio in Review

As of Q1 2026, Blue Owl Capital Holdings held 99 positions worth $372M, up 15% from $324M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Blue Owl Capital Holdings deployed $80.2M of net new capital in Q1 2026, opening 19 new positions and adding to 13 existing holdings. Its largest new stake was Aktis Oncology: 3,161,348 shares worth $56.6M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 64% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Cullinan Oncology, an estimated $5.67M trimmed.

  • Blue Owl Capital Holdings's largest Q1 2026 buy was Aktis Oncology: 3,161,348 shares worth $56.6M.
  • Blue Owl Capital Holdings added most to MapLight Therapeutics in Q1 2026, an estimated $12.1M increase.
  • Blue Owl Capital Holdings's biggest Q1 2026 reduction was Cullinan Oncology, cutting an estimated $5.67M.
  • Blue Owl Capital Holdings fully exited Repare Therapeutics in Q1 2026, selling an estimated $8.95M.
  • Blue Owl Capital Holdings's ten largest holdings make up 69% of its $372M portfolio in Q1 2026.
  • Blue Owl Capital Holdings opened 19 new positions and closed 23 in Q1 2026.
  • Blue Owl Capital Holdings's portfolio value rose 15% quarter-over-quarter to $372M.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2026, filed 14 May 2026.